Polymyositis - Pipeline Insight, 2024

Polymyositis - Pipeline Insight, 2024

DelveInsight’s, “Polymyositis - Pipeline Insight, 2024,” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Polymyositis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Polymyositis Understanding

Polymyositis: Overview

Polymyositis is a type of inflammatory myopathy, which refers to a group of muscle diseases characterized by chronic muscle inflammation and weakness. The muscles affected by Polymyositis are the skeletal muscles (those involved with making movements) on both sides of the body. The disease is more common among women and among black individuals. The exact cause of Polymyositis is unknown. The disease shares many characteristics with autoimmune disorders, which occur when the immune system mistakenly attacks healthy body tissues. In some cases, the disease may be associated with viral infections, connective tissue disorders, or an increased risk for malignancies (cancer). Diagnosis is based on a clinical examination that may include laboratory tests, imaging studies, electromyography, and a muscle biopsy. The most common ages for symptoms of a disease to begin is called age of onset. Age of onset can vary for different diseases and may be used by a doctor to determine the diagnosis. For some diseases, symptoms may begin in a single age range or several age ranges. For other diseases, symptoms may begin any time during a person's life.

""Polymyositis - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Polymyositis pipeline landscape is provided which includes the disease overview and Polymyositis treatment guidelines. The assessment part of the report embraces, in depth Polymyositis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Polymyositis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Polymyositis.
• In the coming years, the Polymyositis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Polymyositis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Polymyositis treatment market. Several potential therapies for Polymyositis are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Polymyositis market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Polymyositis) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Polymyositis Emerging Drugs Chapters

This segment of the Polymyositis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Polymyositis Emerging Drugs

• Ustekinumab: Janssen Pharmaceutical

Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin (IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMARDs) that is used in the management of various inflammatory conditions that involve the activation of IL-12 and IL-23 signalling pathways. Currently, it is in Phase III stage of clinical trial evaluation to treat Polymyositis.

• PN-101: PAEAN Biotechnology

PN-101 the world’s first allogeneic mitochondrial drug candidate for the treatment of polymyositis and dermatomyositis. PN-101 is the first-in-class drug where the main component consists of mitochondria isolated from stem cells. Currently, it is in Phase I/II stage of clinical trial evaluation to treat Polymyositis.

Further product details are provided in the report……..

Polymyositis: Therapeutic Assessment

This segment of the report provides insights about the different Polymyositis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Polymyositis

There are approx. 7+ key companies which are developing the therapies for Polymyositis. The companies which have their Polymyositis drug candidates in the most advanced stage, i.e. phase III include, Janssen Pharmaceutical.

• Phases

DelveInsight’s report covers around 7+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Polymyositis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Polymyositis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Polymyositis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polymyositis drugs.

Polymyositis Report Insights

• Polymyositis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Polymyositis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Polymyositis drugs?
• How many Polymyositis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Polymyositis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Polymyositis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Polymyositis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Janssen Pharmaceutical
• PAEAN Biotechnology
• Kezar Life Sciences
• Roche
• Restem, LLC.
• Viela Bio
• Bristol-Myers Squibb
• ImmunoForge

Key Products

• Ustekinumab
• PN 101
• KZR-616
• Actemra
• Umbilical Cord Lining Stem Cells
• VIB7734
• Abatacept
• PF 1801